retatrutide triple agonist glp-1 gip glucagon phase 3 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide hits 28.3% weight loss

A Danish nationwide registry study, including 116,699 individuals with type 2 diabetes and 116,008 matched controls without diabetes, revealed that treatment with GLP-1 RAs was associated with a lower risk of depression [16]

Across GLP-1 telehealth programs as of April 2026, monthly totals commonly range from roughly $200 to $700 or more depending on compound, subscription tier, and dispensing pathway

Real-world treatment gaps are expected to make follow-up support more visible

It uses Synchronous Ultrasound Parallel Beam Technology (SUPERB) to deliver focused energy at a depth of 1.5mm, where collagen remodeling occurs, with an integrated cooling system (SofCool) protecting the skin surface during treatment